483
Novartis Pharmaceuticals CorporationNovartis Pharmaceuticals Corporation – FDA 483
Record Details
An inspection of Novartis Pharmaceuticals Corporation's gene therapy product manufacturing facility in Morris Plains, NJ, revealed significant deficiencies. The firm's process validation for CTL-019 manufacturing was incomplete, with issues noted in the process performance qualification study and un-evaluated changes to the commercial process. Additionally, the facility failed to initiate or investigate deviations for numerous microbial monitoring action level excursions.
- Product type
- biologics
View Company Profile
ID · c31e1262-2601-41e1-b055-114f96464537
Other documents for Novartis Pharmaceuticals Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.